Key CAR-T Developments in Multiple Myeloma Presented at ASCO, EHA

By Blood Cancer Talks - Last Updated: June 29, 2023

The hosts discuss randomized controlled trials of CAR-T therapies in early relapse multiple myeloma, including the KarMMa-3 trial of idecabtagene vicleucel and the CARTITUDE-4 trial of ciltacabtagene autoleucel.

This episode also features a discussion on clinical trials of GPRC5D-targetted CAR T-cell therapy in multiple myeloma. The hosts outline key data from MCARH109, the POLARIS Trial, the phase I UNIVERSAL trial of ALLO-715 in Multiple Myeloma, and more.

This podcast originally appeared on Blood Cancer Talks.

What are the Controversies Surrounding MRD in Blood Cancers?

What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

HMAs Are ‘Cornerstone’ in High-Risk MDS Treatment, Says Jamile Shammo, MD

Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL

Dr. Samer Al Hadidi Discusses CAR-T MM Data Presented at the FDA ODAC Meeting

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

Key CAR-T Developments in Multiple Myeloma Presented at ASCO, EHA

Related